Feihe (06186) deciphers the early life intestinal microbiota code, ushering in a new era of precise nutrition for infants and young children.

Recently, CHINA FEIHE has made a groundbreaking scientific progress in the field of early infant nutrition and health. The Feihe research and development team, starting from the complex mechanism of the metabolism of core infant gut microbiota by mother's milk prebiotics (human milk oligosaccharides, HMOs), proposed the extensive application of infant nutrition combination based on HMOs and bifidobacteria in the early life diversity health. The research team systematically analyzed the deep mechanisms of both in promoting infant gut health, immune system development, and brain development. The research results not only gained recognition from international authoritative SCI journals but also provided hardcore scientific evidence for mothers to scientifically choose milk and feed their babies accurately. Leveraging this cutting-edge scientific breakthrough, Feihe will continue to iterate and upgrade products based on a concept more suitable for Chinese baby's physique, dedicated to safeguarding the health and growth of thousands of Chinese babies. Research results have been published in the SCI Zone 1 journal "Food & Function." Cracking the "code" of infant gut microbiota, guiding infant feeding with synergistic evolutionary theory Traditional research has mostly focused on the function of individual nutrients, neglecting the uniqueness of early-life host gut microbiota and their natural synergy with breast milk components. Starting from breaking this limitation, the Feihe team proposed the natural "nutrient-consumer" synergistic evolutionary mechanism between HMOs and bifidobacteria. This innovation not only opened up a new direction in research on infant gut microbiota but also proposed new possibilities for industry development. It laid a solid scientific foundation for precise nutritional formula design and provided a new theoretical basis and professional solutions for parents to feed their children scientifically. Deep interaction mechanism between HMOs and bifidobacteria This research goes beyond traditional nutrition cognition, achieving an upgrade from "meeting basic needs" to "actively safeguarding." In this mechanism, HMOs act as prebiotic "nutrients," efficiently consumed by bifidobacteria and rapidly proliferate, stabilizing the beneficial bacteria's advantageous position in the gut, making the baby's gut digestive power stronger and nutrient absorption more efficient. Meanwhile, bifidobacteria metabolize to produce beneficial substances like short-chain fatty acids, forming a mutually beneficial "cross-feeding" network in the gut, which can strengthen the baby's gut barrier and effectively protect gastrointestinal health. Thus, the combination of HMOs and bifidobacteria produces an synergistic effect, becoming the most suitable combination for the nutritional needs of infants and toddlers, meeting the high-quality nutritional needs for their growth and development. In addition, the synergistic action of HMOs and bifidobacteria can not only protect infant gut health but also regulate immune balance, reduce the risk of allergic and other immune-related diseases. At the same time, through the "gut-brain axis" metabolism, key neuroactive substances are produced, providing strong support for infant brain cognition and emotional regulation, helping LIPPO baby in immune and brain development, laying a strong foundation for immunity and seizing the golden advantage in brain development in the early stages of growth. From the laboratory to the bottle: scientific research results accelerate product upgrades As a scientific research enterprise leading the infant formula industry in China, Feihe has always insisted on driving product innovation with breast milk research. This breakthrough in the synergistic mechanism between HMOs and bifidobacteria has rapidly transformed into the core design concept of multiple products, building a gut microbiota and comprehensive nutritional system close to breast milk. Currently, products under the Feihe brand such as Xingfeifan Zhuorui, Xingfeifan Zhuoyu, Qicui, and Jicui series are all iteratively upgraded based on this research framework. Each product incorporates scientifically balanced HMOs and highly active bifidobacteria, aiming to start from the gut microbiota, support the baby's self-protection construction, brain development, and digestive absorption comfort simultaneously - for example, Xingfeifan Zhuoyu can achieve "good digestion and absorption within 3 hours" according to scientific evidence; Qicui clinical data shows a decrease in the number of baby night awakenings by about 62%, and an increase in cognitive ability by 7.7%; Jicui pioneers the "dual-source protection system," internally and externally strengthening the immune barrier. For many years, Feihe has continued high-intensity research and development, leading the "14th Five-Year Plan" key special projects have published 21 papers, applied for 12 patents, built a Chinese independent knowledge system for breast milk research, broke through many bottlenecks such as the "fresh-extracting active process," and achieved 100% self-sufficiency in 11 key raw materials production. Feihe Infant Formula New Product "Jicui" From proposing the development of the "nutrient-consumer" synergistic evolutionary mechanism based on the natural gut microbiota of infants and toddlers to translating it into the core technical language of multiple products, Feihe is using scientific research as the engine to transform scientific development into visible growth benefits for babies. In the future, Feihe will continue to deepen the field of early-life nutrition, pushing the infant nutrition industry towards high-quality development with solutions that are more suited to the physique of Chinese babies.